TipRanks
Omnicell (MX:OMCL)
:OMCL
Mexico Market
OMCL
Omnicell
RESEARCH TOOLSreports

Omnicell (OMCL) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

OMCL Analyst Ratings

Strong Buy
6Ratings
Strong Buy
5 Buy
1 Hold
0 Sell
Based on 6 analysts giving stock ratings to
Omnicell
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

OMCL Stock 12 Month Forecast

Average Price Target

$1,063.70
▲(51.52% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Omnicell in the last 3 months. The average price target is $1,063.70 with a high forecast of $1,227.34 and a low forecast of $944.11. The average price target represents a 51.52% change from the last price of $702.01.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"649":"$649","1228":"$1,228","793.75":"$793.8","938.5":"$938.5","1083.25":"$1,083.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1227.34138995,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.23K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1063.6958712899998,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.06K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":944.1087615,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$944.11</span>\n  </div></div>","useHTML":true}}],"tickPositions":[649,793.75,938.5,1083.25,1228],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,702.01,742.4201069192308,782.8302138384615,823.2403207576923,863.6504276769231,904.0605345961538,944.4706415153846,984.8807484346153,1025.2908553538462,1065.7009622730768,1106.1110691923077,1146.5211761115384,1186.931283030769,{"y":1227.34138995,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,702.01,729.8319900992308,757.6539801984615,785.4759702976922,813.297960396923,841.1199504961537,868.9419405953845,896.7639306946153,924.5859207938461,952.4079108930767,980.2299009923075,1008.0518910915382,1035.873881190769,{"y":1063.6958712899998,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,702.01,720.6329816538462,739.2559633076924,757.8789449615384,776.5019266153846,795.1249082692308,813.747889923077,832.370871576923,850.9938532307692,869.6168348846154,888.2398165384616,906.8627981923078,925.485779846154,{"y":944.1087615,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":961.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":961.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":961.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":961.5,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":961.5,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":961.5,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":961.5,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":772,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":761.16,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":650.89,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":702.01,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":702.01,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":702.01,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$1,227Average Price Target$1,064Lowest Price Target$944.11
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on MX:OMCL
Jessica Tassan
Piper Sandler
Piper Sandler
$849.7→$1,019.64
Buy
45.25%
Upside
Reiterated
10/30/26
Omnicell (OMCL) Gets a Buy from Piper Sandler
BTIG Analyst forecast on MX:OMCL
David Larsen
BTIG
BTIG
―
Hold
―
Reiterated
10/29/26
Analysts Offer Insights on Healthcare Companies: Omnicell (NASDAQ: OMCL), Establishment Labs Holdings (NASDAQ: ESTA) and Stryker (NYSE: SYK)
Bank of America Securities Analyst forecast on MX:OMCL
Allen Lutz
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
10/16/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wells Fargo Analyst forecast on MX:OMCL
Stan Berenshteyn
Wells Fargo
Wells Fargo
$944.11
Buy
34.49%
Upside
Assigned
10/14/26
Analysts Offer Insights on Healthcare Companies: Contineum Therapeutics, Inc. Class A (NASDAQ: CTNM) and Omnicell (NASDAQ: OMCL)
Craig-Hallum Analyst forecast on MX:OMCL
Matt Hewitt
Craig-Hallum
Craig-Hallum
―
Buy
―
Reiterated
09/02/26
Analysts' Top Healthcare Picks: uniQure (QURE), Alumis Inc. (ALMS)
KeyBanc Analyst forecast on MX:OMCL
Scott Schoenhaus
KeyBanc
KeyBanc
$1,227.34
Buy
74.83%
Upside
Reiterated
08/24/26
Analysts Offer Insights on Healthcare Companies: Omnicell (NASDAQ: OMCL) and Guardant Health (NASDAQ: GH)
Freedom Capital Markets Analyst forecast on MX:OMCL
Eugene Mannheimer
Freedom Capital Markets
Freedom Capital Markets
$1,208.46→$1,132.93
Buy
61.38%
Upside
Reiterated
07/31/26
We reiterate our Buy rating on Omnicell (OMCL) following Q2 2026 results that beat our estimates on profitability.
Benchmark Co. Analyst forecast on MX:OMCL
Bill Sutherland
Benchmark Co.
Benchmark Co.
$1,132.93
Buy
61.38%
Upside
Reiterated
07/30/26
Analysts Offer Insights on Healthcare Companies: Omnicell (NASDAQ: OMCL), Daiichi Sankyo Company (Other OTC: DSKYF) and GE Healthcare Technologies Inc (NASDAQ: GEHC)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on MX:OMCL
Jessica Tassan
Piper Sandler
Piper Sandler
$849.7→$1,019.64
Buy
45.25%
Upside
Reiterated
10/30/26
Omnicell (OMCL) Gets a Buy from Piper Sandler
BTIG Analyst forecast on MX:OMCL
David Larsen
BTIG
BTIG
―
Hold
―
Reiterated
10/29/26
Analysts Offer Insights on Healthcare Companies: Omnicell (NASDAQ: OMCL), Establishment Labs Holdings (NASDAQ: ESTA) and Stryker (NYSE: SYK)
Bank of America Securities Analyst forecast on MX:OMCL
Allen Lutz
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
10/16/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wells Fargo Analyst forecast on MX:OMCL
Stan Berenshteyn
Wells Fargo
Wells Fargo
$944.11
Buy
34.49%
Upside
Assigned
10/14/26
Analysts Offer Insights on Healthcare Companies: Contineum Therapeutics, Inc. Class A (NASDAQ: CTNM) and Omnicell (NASDAQ: OMCL)
Craig-Hallum Analyst forecast on MX:OMCL
Matt Hewitt
Craig-Hallum
Craig-Hallum
―
Buy
―
Reiterated
09/02/26
Analysts' Top Healthcare Picks: uniQure (QURE), Alumis Inc. (ALMS)
KeyBanc Analyst forecast on MX:OMCL
Scott Schoenhaus
KeyBanc
KeyBanc
$1,227.34
Buy
74.83%
Upside
Reiterated
08/24/26
Analysts Offer Insights on Healthcare Companies: Omnicell (NASDAQ: OMCL) and Guardant Health (NASDAQ: GH)
Freedom Capital Markets Analyst forecast on MX:OMCL
Eugene Mannheimer
Freedom Capital Markets
Freedom Capital Markets
$1,208.46→$1,132.93
Buy
61.38%
Upside
Reiterated
07/31/26
We reiterate our Buy rating on Omnicell (OMCL) following Q2 2026 results that beat our estimates on profitability.
Benchmark Co. Analyst forecast on MX:OMCL
Bill Sutherland
Benchmark Co.
Benchmark Co.
$1,132.93
Buy
61.38%
Upside
Reiterated
07/30/26
Analysts Offer Insights on Healthcare Companies: Omnicell (NASDAQ: OMCL), Daiichi Sankyo Company (Other OTC: DSKYF) and GE Healthcare Technologies Inc (NASDAQ: GEHC)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AMRXAmneal Pharmaceuticals
DNTHDianthus Therapeutics
REPLReplimune Group
VSTMVerastem
OVIDOvid Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Omnicell

3 Months
Stan BerenshteynWells Fargo
Success Rate
15/21 ratings generated profit
71%
Average Return
+9.60%
Copying Stan Berenshteyn's trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +9.60% per trade.
1 Year
Stan BerenshteynWells Fargo
Success Rate
13/21 ratings generated profit
62%
Average Return
+5.36%
Copying Stan Berenshteyn's trades and holding each position for 1 Year would result in 61.90% of your transactions generating a profit, with an average return of +5.36% per trade.
2 Years
Stan BerenshteynWells Fargo
Success Rate
13/21 ratings generated profit
62%
Average Return
+2.73%
Copying Stan Berenshteyn's trades and holding each position for 2 Years would result in 61.90% of your transactions generating a profit, with an average return of +2.73% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

OMCL Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
6
5
5
4
1
Buy
5
5
6
6
5
Hold
1
0
0
0
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
12
10
11
10
7
In the current month, OMCL has received 6 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. OMCL average Analyst price target in the past 3 months is 1,063.70.
Each month's total comprises the sum of three months' worth of ratings.

OMCL Financial Forecast

OMCL Earnings Forecast

Next quarter’s earnings estimate for OMCL is $7.72 with a range of $6.76 to $8.45. The previous quarter’s EPS was $10.90. OMCL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year OMCL has Performed in-line its overall industry.
Next quarter’s earnings estimate for OMCL is $7.72 with a range of $6.76 to $8.45. The previous quarter’s EPS was $10.90. OMCL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year OMCL has Performed in-line its overall industry.

OMCL Sales Forecast

Next quarter’s sales forecast for OMCL is $5.68B with a range of $5.57B to $5.96B. The previous quarter’s sales results were $5.78B. OMCL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year OMCL has Performed in-line its overall industry.
Next quarter’s sales forecast for OMCL is $5.68B with a range of $5.57B to $5.96B. The previous quarter’s sales results were $5.78B. OMCL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year OMCL has Performed in-line its overall industry.

OMCL Stock Forecast FAQ

What is MX:OMCL’s average 12-month price target, according to analysts?
Based on analyst ratings, Omnicell’s 12-month average price target is 1,063.70.
    What is MX:OMCL’s upside potential, based on the analysts’ average price target?
    Omnicell has 51.52% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Omnicell a Buy, Sell or Hold?
          Omnicell has a consensus rating of Strong Buy, which is based on 5 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Omnicell’s share price target?
            The average share price target for Omnicell is 1,063.70. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $1,227.34 ,and the lowest forecast is $944.11. The average share price target represents 51.52% Increase from the current price of $702.01.
              What do analysts say about Omnicell?
              Omnicell’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of Omnicell?
                To buy shares of MX:OMCL, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.